Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 6,44€(+2,06%). Der Median liegt bei 5,71€(−9,51%).
Kaufen | 5 |
Halten | 1 |
Verkaufen | 2 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025
STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12:01 a.m.» Mehr auf accessnewswire.com
Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis
SAN DIEGO--(BUSINESS WIRE)--Telesis Bio Inc. (OTCMKTS: TBIO), a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced a new license agreement with Regeneron Pharmaceuticals, Inc. to deploy Telesis Bio's revolutionary Gibson SOLA™ platform at its R&D core facilities. This will help Regeneron adopt automated, high-throughput, on-demand gene synthesis in their own labs. Using Gibson SOLA at s.» Mehr auf businesswire.com
Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer
BOSTON , May 21, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dmytruk, the Company's Chief Financial Officer, intends to resign from his role at the Company on May 30, 2025 to accept a position at another organization and Steven Coen, CPA, the Company's Chief Accounting Officer, will become Chief Financial Officer, effective upon Mr. Dmytruk's resignation.» Mehr auf prnewswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 44,66 Mio | 27,04% |
Bruttoeinkommen | 33,53 Mio | 127,96% |
Nettoeinkommen | −84,08 Mio | 45,31% |
EBITDA | −63,16 Mio | 58,72% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 384,30 Mio€ |
Anzahl Aktien | 58,53 Mio |
52 Wochen-Hoch/Tief | 19,84€ - 4,39€ |
Dividenden | Nein |
Beta | 1,26 |
KGV (PE Ratio) | −0,86 |
KGWV (PEG Ratio) | −0,06 |
KBV (PB Ratio) | 0,63 |
KUV (PS Ratio) | 1,84 |
Unternehmensprofil
Name | Ginkgo Bioworks Holdings A Aktie |
CEO | Dr. Jason Kelly Ph.D. |
Mitarbeiter | 834 |
Assets entdecken
Shareholder von Ginkgo Bioworks Holdings A Aktie investieren auch in folgende Assets